PCI Biotech Holding ASA
OSE:PCIB
PCI Biotech Holding ASA
Research & Development
PCI Biotech Holding ASA
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PCI Biotech Holding ASA
OSE:PCIB
|
Research & Development
-kr17.3m
|
CAGR 3-Years
38%
|
CAGR 5-Years
25%
|
CAGR 10-Years
7%
|
|
|
Hofseth Biocare ASA
OSE:HBC
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
U
|
Ultimovacs ASA
OSE:ULTI
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
Research & Development
-kr72.6m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
N/A
|
|
|
Arcticzymes Technologies ASA
OSE:AZT
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
Thor Medical ASA
OSE:TRMED
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
PCI Biotech Holding ASA
Glance View
PCI Biotech Holding ASA engages in the research and development of biopharmaceutical products for cancer treatment. The company is headquartered in Oslo, Oslo. The company went IPO on 2008-06-18. Its activities are focused on the commercialization of a patented photochemical drug delivery technology for use in the localized cancer treatment. The Company’s products are based on the Photochemical Internalization (PCI) technology for light-directed drug delivery, used to enhance the effect of drugs by targeted illumination of the diseased areas of the body. The company focuses primarily on the drug candidate Amphinex, developed for treatment of head and neck cancer and bile duct cancer, as well as on the development of PCI for vaccination. As of December 31, 2011, it had a wholly owned subsidiary PCI Biotech AS and an affiliate PCIO Biotech Utibu, located in Iceland.
See Also
What is PCI Biotech Holding ASA's Research & Development?
Research & Development
-17.3m
NOK
Based on the financial report for Jun 30, 2025, PCI Biotech Holding ASA's Research & Development amounts to -17.3m NOK.
What is PCI Biotech Holding ASA's Research & Development growth rate?
Research & Development CAGR 10Y
7%
Over the last year, the Research & Development growth was 24%. The average annual Research & Development growth rates for PCI Biotech Holding ASA have been 38% over the past three years , 25% over the past five years , and 7% over the past ten years .
